| Market Capitalization (Millions $) |
1,809 |
| Shares
Outstanding (Millions) |
114 |
| Employees |
401 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-236 |
| Cash Flow (TTM) (Millions $) |
255 |
| Capital Exp. (TTM) (Millions $) |
0 |
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company that is focused on developing transformative medicines for patients who have unmet medical needs. They are committed to bridging the gap between science and patients, and they are working hard to develop therapies that can change the course of disease.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. Centessa is a publicly traded company on the NASDAQ stock exchange and is traded under the symbol CNTA. They have a diverse pipeline of drug candidates that are focused on a variety of therapeutic indications, including immuno-oncology, hematology, and genetic diseases.
One of the hallmarks of Centessa is its unique business model, which is based on a "hub-and-spoke" approach. They have acquired a number of smaller biotech companies and are operating them as individual subsidiaries, each with its own research and development team. This allows Centessa to harness the power of multiple organizations and bring together a range of expertise and resources.
The company's pipeline includes a number of promising drug candidates, including CNV1014802, which is being developed for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder that causes the formation of bone in soft tissue. They also have several immuno-oncology candidates, including CMP-001, a toll-like receptor agonist that is being developed in conjunction with Tecentriq for the treatment of multiple types of cancer.
In addition to its pipeline, Centessa is also actively pursuing partnerships and collaborations with other companies and organizations in order to expand its reach and accelerate the development of its drug candidates. They are committed to developing innovative and effective therapies for patients in need, and they are rapidly becoming a major player in the biopharmaceutical industry.
Company Address: 3rd Floor Cheshire 0
Company Phone Number: 468-5770 Stock Exchange / Ticker: NASDAQ CNTA
|
